Viatris (VTRS) Cost of Revenue (2020 - 2026)
Viatris' (VTRS) quarterly Cost of Revenue came in at $2.4 billion in Q1 2026, up 12.74% year-on-year from $2.1 billion in Q1 2025, and down 7.67% quarter-over-quarter from $2.6 billion in Q4 2025.
Viatris (VTRS) Cost of Revenue (2020 - 2026) Analysis & Trends
Viatris' Cost of Revenue history runs 7 years deep, the most recent figure standing at $2.4 billion for Q1 2026.
- On a quarterly basis, Cost of Revenue rose 12.74% year-over-year to $2.4 billion in Q1 2026; TTM through Mar 2026 was $9.6 billion, a 5.57% increase from a year earlier, with the FY2025 full-year figure at $9.3 billion, up 1.87% from the prior year.
- Cost of Revenue declined to $2.4 billion in Q1 2026 per VTRS's latest filing, from $2.6 billion in the prior quarter.
- Across five years, Cost of Revenue topped out at $2.6 billion in Q4 2022 and bottomed at $2.1 billion in Q1 2025.
- The 5-year median for Cost of Revenue is $2.3 billion (2024), against an average of $2.3 billion.
- Across the five-year window, Cost of Revenue decreased 26.72% in 2022 and climbed 12.74% in 2026, its largest moves.
- Year by year, Cost of Revenue stood at $2.6 billion in 2022, then decreased by 13.88% to $2.2 billion in 2023, then gained by 3.23% to $2.3 billion in 2024, then grew by 10.49% to $2.6 billion in 2025, then declined by 7.67% to $2.4 billion in 2026.
- Per Business Quant, the three latest VTRS Cost of Revenue figures stand at $2.4 billion (Q1 2026), $2.6 billion (Q4 2025), and $2.4 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 2.01 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 641.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 2.59 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 133.40 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 2.36 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 13.80 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 586.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 46.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.36 Bn |
| Mar 31, 2026 | 2.36 Bn |
| Dec 31, 2025 | 2.56 Bn |
| Dec 31, 2025 | 2.56 Bn |
| Sep 30, 2025 | 2.39 Bn |
| Sep 30, 2025 | 2.39 Bn |
| Jun 30, 2025 | 2.25 Bn |
| Jun 30, 2025 | 2.25 Bn |
| Mar 31, 2025 | 2.09 Bn |
| Mar 31, 2025 | 2.09 Bn |
| Dec 31, 2024 | 2.31 Bn |
| Dec 31, 2024 | 2.31 Bn |
| Sep 30, 2024 | 2.29 Bn |
| Sep 30, 2024 | 2.29 Bn |
| Jun 30, 2024 | 2.35 Bn |
| Jun 30, 2024 | 2.35 Bn |
| Mar 31, 2024 | 2.16 Bn |
| Mar 31, 2024 | 2.16 Bn |
| Dec 31, 2023 | 2.24 Bn |
| Dec 31, 2023 | 2.24 Bn |